Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

Affiliations

• ¹ Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. n.vandedonk@amsterdamumc.nl.
• ² Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
• ³ University of Alabama at Birmingham, Birmingham, AL, USA.
• ⁴ University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain.
• ⁵ Winship Cancer Institute, Emory University, Atlanta, GA, USA.
• ⁶ Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
• ⁷ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
• ⁸ Janssen Research & Development, Bridgewater, NJ, USA.
• ⁹ Janssen Research & Development, Titusville, NJ, USA.
• ¹⁰ Janssen Research & Development, Spring House, PA, USA.
• ¹¹ Janssen Research & Development, Raritan, NJ, USA.
• ¹² Janssen Sciences Ireland, Dublin, Ireland.
• ¹³ Memorial Sloan Kettering Cancer Center, New York, NY, USA.